MONTREAL, QUEBEC -- (MARKET WIRE) -- September 07, 2006 -- Ecopia BioSciences Inc. (TSX: EIA) is pleased to announce that it was granted today by the United States Patent and Trademark Office (USPTO) United States Patent No. 7,101,872 directed to Farnesyl Dibenzodiazepinone and Processes for its Production. This important patent provides the Company with exclusive rights in the United States relating to its lead anti-cancer drug candidate's composition-of-matter. Such claims to the structure of a compound are the most solid protection that can be obtained on a potential drug because they cover any medical and non-medical use of the compound. These claims are available where novelty resides in the structure of the compound as opposed to only in its utility.
